识别增殖性狼疮肾炎的多中心临床模型
该多中心回顾性研究纳入443例经活检证实的狼疮肾炎患者,开发并外部验证了一种基于常规临床变量的无创模型用于识别增殖性狼疮肾炎(PLN)。最终模型包含7个预测因子,开发队列AUC为0.852,外部验证队列AUC为0.895,校准可接受,决策曲线分析提示潜在临床效用。
要点
- 模型含7个预测因子:淋巴细胞百分比、血尿、白细胞尿、eGFR、尿酸、抗dsDNA阳性、C3。
- 开发队列AUC 0.852,外部验证队列AUC 0.895,校准可接受。
- 该无创模型可能为狼疮肾炎患者风险分层和临床评估提供实用工具。
核心结论
- 开发并外部验证了基于常规临床变量的无创模型,用于识别增殖性狼疮肾炎,可能辅助风险分层和临床评估。
研究设计与样本
- 多中心回顾性研究,纳入5个中心443例经活检证实的狼疮肾炎患者;开发队列为A中心337例,外部验证队列为B至E中心106例。
- 采用单变量分析和LASSO回归筛选候选预测因子,多变量逻辑回归构建最终列线图;内部验证采用5折交叉验证和bootstrap重采样。
主要发现
- 最终模型纳入7个预测因子:淋巴细胞百分比、血尿、白细胞尿、估算肾小球滤过率、尿酸、抗dsDNA阳性、C3。
- 模型在开发队列的AUC为0.852,在外部验证队列的AUC为0.895。
- 两个队列校准均可接受,决策曲线分析提示潜在临床效用。
关键数值与推荐
- 开发队列AUC 0.852,外部验证队列AUC 0.895。
临床怎么用
- 该模型基于常规可获得的临床变量,可能为狼疮肾炎患者提供无创的增殖性病变风险分层工具,辅助临床评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Proliferative lupus nephritis (PLN) is associated with poorer renal outcomes than non-proliferative lupus nephritis. Although kidney biopsy remains the gold standard for histologic classification, its use may be limited by invasiveness, contraindications, and limited healthcare access. We aimed to develop and externally validate a noninvasive model for identifying PLN. METHODS: In this multicenter retrospective study, 443 patients with biopsy-confirmed lupus nephritis from five centers were included. The development cohort comprised 337 patients from center A, and the external validation cohort included 106 patients from centers B to E. Candidate predictors were screened using univariable analysis and least absolute shrinkage and selection operator regression, followed by multivariable logistic regression to construct the final nomogram. Internal validation was performed using 5-fold cross-validation and bootstrap resampling. RESULTS: The final model incorporated seven predictors, namely lymphocyte percentage, hematuria, leukocyturia, estimated glomerular filtration rate, uric acid, anti-dsDNA positivity, and C3. The model showed good discrimination, with an area under the receiver operating characteristic curve of 0.852 in the development cohort and 0.895 in the external validation cohort. Calibration was acceptable in both cohorts, and decision curve analysis suggested potential clinical utility. CONCLUSION: We developed and externally validated a noninvasive clinical model based on routinely available clinical variables for identifying PLN. This model may provide a practical tool for risk stratification and support clinical evaluation in patients with lupus nephritis.
引用
- Lin Z, Wang W, Li X, et al. A clinical model for identifying proliferative lupus nephritis: a multicenter study. Rheumatology (Oxford). 2026. PMID: 42873590. doi:10.1093/rheumatology/keag570
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。